AML therapy with oral, small-molecule inhibitors of mutant IDH1 and mutant IDH2, respectively, has shown promising results (Stein et al., 2017; DiNardo et al., 2018) indicating that metabolic targeting is an effective approach for AML therapy. Here, IDH1 is linked to acute myeloid leukemia.